ClinicalTrials.gg
CompletedNCT01218659Updated Nov 1, 2018Results posted

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

A Phase 3 interventional study of migalastat hydrochloride and agalsidase in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 25 sites in 10 countries. Open to participants aged 16 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-11-01.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
16 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
5th of 20
68 · median 20
Started
2011
with 4 others
Phase 3
11 of 20
2 open now
Registered
8th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 5th largest by enrollment, is one of 5 that started in 2011, is one of 11 in phase 3, and was the 8th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 16 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

Study to compare the efficacy and safety of migalastat and enzyme replacement therapy (ERT) in male and female participants with Fabry disease who are currently receiving ERT and who have an alpha galactosidase-A (α Gal-A) mutation that is amenable to migalastat, based on the clinical trial human embryonic kidney cell (HEK) assay.

Read the detailed description

This was a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of 150 milligrams (mg) of migalastat hydrochloride (migalastat) (equivalent to 123 mg of migalastat) once every other day (QOD) and ERT in male and female participants with Fabry disease who were receiving ERT and who have an α Gal-A mutation that is amenable to migalastat, based on the clinical trial HEK assay. This was a 2-part study. Part 1, the 18-month randomized phase, evaluated participants who received either migalastat 150 mg QOD or ERT per prescribing physicians' instructions for efficacy and safety. Part 2, the optional 12-month open-label extension (OLE) phase in which all participants received migalastat, also explored efficacy and safety. For Part 2, all participants who received ERT in Part 1 were given migalastat. Data presented in this posting include efficacy data from the 18-month randomized period and safety data from the entire study (18-month randomized period and 12-month optional OLE [total of 30 months]).

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • Galafold
  • AT1001
  • Migalastat
04

Who can participate

Ages eligible
16 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 16 and 74 diagnosed with Fabry disease
  • Confirmed α Gal-A mutation that is amenable to migalastat, based on the clinical trial HEK assay
  • Participant has been on ERT for at least 12 months before screening/baseline
  • Dose level and regimen of ERT have been stable for 3 months before screening/baseline and is at least 80% of the currently labeled dose and regimen for this time period
  • (GFR) ≥ 30 milliliter (mL)/minute (min) /1.73 m\^2
  • Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for at least 4 weeks before screening/baseline
  • Women who can become pregnant and all men agree to be sexually abstinent or use medically accepted methods of throughout the duration of the study and for up to 30 days after last dose of study medication
  • Participant is willing and able to provide written and assent if applicable

Exclusion criteria

Exclusion Criteria:

  • Participant has undergone, or is scheduled to undergo, kidney transplantation or any other solid organ transplantation
  • Participant is on regular dialysis that is specifically for the treatment of chronic kidney disease
  • Participant has had a documented , stroke, unstable angina, or myocardial infarction within the 3 months before screening/baseline
  • Participant has unstable cardiac disease in the opinion of the investigator (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or (NYHA) class III or IV congestive heart failure)
  • Pregnant or breast-feeding
  • History of allergy or sensitivity to study medication (including ) or other iminosugars (for example, miglustat, miglitol)
  • Participant has absolute to iohexol and/or inability to undergo iohexol testing
  • Participant requires treatment with Glyset® (miglitol), or Zavesca® (miglustat)
  • Participant received any /experimental drug, biologic or device within 30 days of screening/baseline
  • Any intercurrent illness or condition that may preclude the participant from fulfilling the study requirements or suggests to the investigator that the participant may have an unacceptable risk by participating in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Migalastat

    Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.

    Drug: migalastat hydrochloride

  • Active comparator
    ERT

    Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given \>80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.

    Biological: agalsidase

Interventions

  • 150-mg capsule administered orally QOD

    Also known as: AT1001, Migalastat, Galafold

  • Biologicalagalsidase

    Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information

    Also known as: agalsidase beta; Fabrazyme, agalsidase alfa; Replagal

06

What researchers measure

Primary outcomes

  1. Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate

    To assess renal function, measured glomerular filtration rate (GFR) was measured by the plasma clearance of unlabeled iohexol (mGFR-iohexol), a non-ionic contrast agent. The annualized rate of change in mGFR-iohexol from Baseline to Month 18 was analyzed using an analysis of covariance (ANCOVA) model with the following factors as covariates: treatment group, sex, age, Baseline GFR (mGFR-iohexol), and Baseline 24-hour (hr) urine protein. A threshold of \<2.2 milliliter (mL)/minute (min)/1.73 meter squared (m\^2)/year was established to compare migalastat to ERT. This difference of 2.2 mL/min/1.73 m2/year is based on the smallest expected rate of decline in estimated glomerular filtration rate (eGFR) for participants treated with agalsidase alfa for 18 months.

    Time frame: Baseline to Month 18

  2. Annualized Rate Of Change From Baseline To Month 18 In eGFR

    The eGFR assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was calculated using the following: eGFR-CKD-EPI = 141 x min (Serum Creatinine/κ,1)\^(α) x max(Serum Creatinine/κ,1)\^(-1.209) x 0.993\^(Age) x 1.1018 (if female) x 1.159 (if African American or black) where: κ is 0.7 for females and 0.9 for males; α is -0.329 for females and -0.411 for males; min indicates the minimum of Serum Creatinine/κ or 1; max indicates the maximum of Serum Creatinine/κ or 1. The annualized rate of change in eGFR-CKD-EPI from Baseline to Month 18 was analyzed using an ANCOVA model with the following factors as covariates: treatment group, sex, age, Baseline GFR (eGFR-CKD-EPI), and Baseline 24-hr urine protein. A threshold of \<2.2 mL/min/1.73m\^2/year was established to compare migalastat to ERT. This difference of 2.2 mL/min/1.73 m2/year is based on the smallest expected rate of decline in eGFR for participants treated with agalsidase alfa for 18 months.

    Time frame: Baseline to Month 18

Secondary outcomes

  1. Annualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation

    The GFR estimated by the Modification Of Diet In Renal Disease equation (eGFR-MDRD) was calculated using the following equation: eGFR-MDRD = 175 x (Serum Creatinine)\^(-1.154) x (Age)\^(-0.203) x 1.212 (if participant's race is black or African American) x 0.742 (if participant is female). The eGFR-MDRD from Baseline to Month 18 was analyzed using an ANCOVA model with the following factors as covariates: treatment group, sex, age, Baseline GFR (eGFR-CKD-EPI), and Baseline 24-hr urine protein.

    Time frame: Baseline to Month 18

07

Results

Posted Nov 1, 2018

Participant flow

18-Month Randomized Period
Participant flow — 18-Month Randomized Period
MilestoneMigalastat (0-18 Months)ERT (0-18 Months)All Migalastat (0-30 Months)
Started36240
Safety population36210
Completed34180
Not completed260
Withdrew: Withdrawal by subject230
Withdrew: Did not receive study drug030
12-Month OLE
Participant flow — 12-Month OLE
MilestoneMigalastat (0-18 Months)ERT (0-18 Months)All Migalastat (0-30 Months)
Started0052
Safety population0051
Modified intent-to-treat (mitt)0046
Completed0042
Not completed0010
Withdrew: Withdrawal by subject002
Withdrew: Physician decision001
Withdrew: Lost to follow-up001
Withdrew: Pregnancy001
Withdrew: Lack of efficacy001
Withdrew: Declined to participate in the ole004

Outcome measures

PrimaryAnnualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate

To assess renal function, measured glomerular filtration rate (GFR) was measured by the plasma clearance of unlabeled iohexol (mGFR-iohexol), a non-ionic contrast agent. The annualized rate of change in mGFR-iohexol from Baseline to Month 18 was analyzed using an analysis of covariance (ANCOVA) model with the following factors as covariates: treatment group, sex, age, Baseline GFR (mGFR-iohexol), and Baseline 24-hour (hr) urine protein. A threshold of \<2.2 milliliter (mL)/minute (min)/1.73 meter squared (m\^2)/year was established to compare migalastat to ERT. This difference of 2.2 mL/min/1.73 m2/year is based on the smallest expected rate of decline in estimated glomerular filtration rate (eGFR) for participants treated with agalsidase alfa for 18 months.

Time frame:
Baseline to Month 18
Reported as:
Least squares mean · mL/min/1.73 m^2/year
Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate
mL/min/1.73 m^2/yearMigalastat (0-18 Months)ERT (0-18 Months)
Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate-4.35 (-7.65 to -1.06)-3.24 (-7.81 to 1.33)
PrimaryAnnualized Rate Of Change From Baseline To Month 18 In eGFR

The eGFR assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was calculated using the following: eGFR-CKD-EPI = 141 x min (Serum Creatinine/κ,1)\^(α) x max(Serum Creatinine/κ,1)\^(-1.209) x 0.993\^(Age) x 1.1018 (if female) x 1.159 (if African American or black) where: κ is 0.7 for females and 0.9 for males; α is -0.329 for females and -0.411 for males; min indicates the minimum of Serum Creatinine/κ or 1; max indicates the maximum of Serum Creatinine/κ or 1. The annualized rate of change in eGFR-CKD-EPI from Baseline to Month 18 was analyzed using an ANCOVA model with the following factors as covariates: treatment group, sex, age, Baseline GFR (eGFR-CKD-EPI), and Baseline 24-hr urine protein. A threshold of \<2.2 mL/min/1.73m\^2/year was established to compare migalastat to ERT. This difference of 2.2 mL/min/1.73 m2/year is based on the smallest expected rate of decline in eGFR for participants treated with agalsidase alfa for 18 months.

Time frame:
Baseline to Month 18
Reported as:
Least squares mean · mL/min/1.73 m^2/year
Annualized Rate Of Change From Baseline To Month 18 In eGFR
mL/min/1.73 m^2/yearMigalastat (0-18 Months)ERT (0-18 Months)
Annualized Rate Of Change From Baseline To Month 18 In eGFR-0.40 (-2.27 to 1.48)-1.03 (-3.64 to 1.58)
SecondaryAnnualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation

The GFR estimated by the Modification Of Diet In Renal Disease equation (eGFR-MDRD) was calculated using the following equation: eGFR-MDRD = 175 x (Serum Creatinine)\^(-1.154) x (Age)\^(-0.203) x 1.212 (if participant's race is black or African American) x 0.742 (if participant is female). The eGFR-MDRD from Baseline to Month 18 was analyzed using an ANCOVA model with the following factors as covariates: treatment group, sex, age, Baseline GFR (eGFR-CKD-EPI), and Baseline 24-hr urine protein.

Time frame:
Baseline to Month 18
Reported as:
Least squares mean · mL/min/1.73 m^2/year
Annualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation
mL/min/1.73 m^2/yearMigalastat (0-18 Months)ERT (0-18 Months)
Annualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation-1.51 (-3.43 to 0.40)-1.53 (-4.20 to 1.13)

Adverse events

Collected over Adverse Event (AE) data were collected from the time of signing informed consent at screening/baseline through the follow-up visit (1 mo. after the last treatment in the optional OLE/after the 18-month Randomized Period if the participant did not enroll in the OLE), for up to 30 months. Because participants in the Migalastat (0-18 mo.) and ERT (0-18 mo.) groups were combined into the All Migalastat (0-30 mo.) group, AEs for those groups are included in the All Migalastat (0-30 mo.) group AEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat (0-18 Months)—7/36 (19.4%)34/36 (94.4%)
ERT (0-18 Months)—7/21 (33.3%)20/21 (95.2%)
All Migalastat (0-30 Months)—16/51 (31.4%)50/51 (98%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventMigalastat (0-18 Months)ERT (0-18 Months)All Migalastat (0-30 Months)
Chest painGeneral disorders3/360/213/51
ObesityMetabolism and nutrition disorders1/361/212/51
Device malfunctionGeneral disorders0/361/211/51
Transient ischaemic attackNervous system disorders0/361/211/51
Cardiac failure chronicCardiac disorders0/361/211/51
DyspnoeaRespiratory, thoracic and mediastinal disorders0/361/211/51
Hernial eventrationGastrointestinal disorders0/361/211/51
Abdominal painGastrointestinal disorders0/361/211/51
Vision blurredEye disorders0/361/211/51
VertigoEar and labyrinth disorders0/361/211/51
Most frequent other events
Showing 10 of 56
Most frequent other events
EventMigalastat (0-18 Months)ERT (0-18 Months)All Migalastat (0-30 Months)
NasopharyngitisInfections and infestations12/367/2121/51
HeadacheNervous system disorders9/365/2116/51
CoughRespiratory, thoracic and mediastinal disorders3/365/218/51
InfluenzaInfections and infestations5/364/2112/51
DiarrhoeaGastrointestinal disorders5/362/2111/51
DizzinessNervous system disorders6/362/218/51
NauseaGastrointestinal disorders5/362/218/51
VomitingGastrointestinal disorders3/363/218/51
BronchitisInfections and infestations2/363/215/51
SinusitisInfections and infestations3/363/214/51

Baseline characteristics

Safety Population: All randomized participants who received at least 1 dose of migalastat or ERT.

Age, Continuous
Age, Continuous(years)Migalastat (0-18 Months)ERT (0-18 Months)Total
Mean50.5 ± 13.7646.3 ± 14.9148.9 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat (0-18 Months)ERT (0-18 Months)Total
Female201232
Male16925
08

Study locations

25 sites
  • Los Angeles, California 90048, United States
  • Aurora, Colorado 80045, United States
  • Decatur, Georgia 30033, United States
  • Grand Rapids, Michigan 49525, United States
  • Portland, Oregon 97239, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Fairfax, Virginia 22030, United States
  • Milwaukee, Wisconsin 53226, United States
  • Parkville, Victoria 03050, Australia
  • Perth, West Australia 6000, Australia
  • Vienna, 1090, Austria
  • Edegem, 2650, Belgium
  • Sao Paulo, 14048-900, Brazil
  • Copenhagen, 2100, Denmark
  • Garches, 92380, France
  • Lille, 59037, France
  • Firenze, 50129, Italy
  • Niigata, 951-8520, Japan
  • Osaka, 545-8586, Japan
  • Osaka, 565-0871, Japan
  • Tokyo, 105-8471, Japan
  • Cambridge, CB2 0QQ, United Kingdom
  • London, NW3 2QG, United Kingdom
  • London, WC1N 3BG, United Kingdom
  • Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020 Sep-Oct;131(1-2):219-228. doi: 10.1016/j.ymgme.2020.07.007. Epub 2020 Aug 15. PubMed 33012654 ↗
  • Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, Krusinska E, Schiffmann R. Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021 Jan;23(1):192-201. doi: 10.1038/s41436-020-00968-z. Epub 2020 Sep 30. Erratum In: Genet Med. 2021 Jan;23(1):238. doi: 10.1038/s41436-020-01041-5. PubMed 32994552 ↗
  • Haninger-Vacariu N, El-Hadi S, Pauler U, Foretnik M, Kain R, Prohaszka Z, Schmidt A, Skuban N, Barth JA, Sunder-Plassmann G. Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report. Case Rep Obstet Gynecol. 2019 Dec 21;2019:1030259. doi: 10.1155/2019/1030259. eCollection 2019. PubMed 31934472 ↗
  • Narita I, Ohashi T, Sakai N, Hamazaki T, Skuban N, Castelli JP, Lagast H, Barth JA. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study. Clin Exp Nephrol. 2020 Feb;24(2):157-166. doi: 10.1007/s10157-019-01810-w. Epub 2019 Dec 30. PubMed 31889231 ↗
  • Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10. Erratum In: J Med Genet. 2018 Jun;55(6):422-429. doi: 10.1136/jmedgenet-2016-104178corr1. PubMed 27834756 ↗
  • Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22. PubMed 27657681 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in May 2014, 32 months.

Results were first posted in Nov 2018, 4 years 5 months after primary completion. A results delay was requested in Jun 2015.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2010
First posted
Oct 11, 2010
StartActual
Sep 8, 2011
Primary completionActual
May 27, 2014
CompletionActual
May 28, 2015
Results delay requested
Jun 25, 2015
Results first posted
Nov 1, 2018
Last update
Nov 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01218659
Responsible party
Sponsor
First posted
Oct 11, 2010
Start date
Sep 8, 2011
Primary completion
May 27, 2014
Completion
May 28, 2015
Results posted
Nov 1, 2018
Last update
Nov 1, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion